Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07456891) titled 'Remibrutinib Open Label Roll-over Post-trial Access Protocol' on March 3.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Novartis Pharmaceuticals

Condition: Indication of the Parent Protocol

Intervention: Drug: Remibrutinib

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: April 10, 2026

Target Sample Size: 212

To know more, visit https://clinicaltrials.gov/study/NCT07456891

Published by HT Digital Content Services with permission from Healt...